Performance in Initiating - Q1: 2018/2019 (1st July 2017 - 30th June 2018)

Research Ethics Committee Reference Number	IRAS number	Name of Trial	Site Invited	Site Selected	HRA Approval	Site Confirmed by Sponsor	Site Confirmed	Non Confirmation Status	Site Ready to Start	First Patient Recruited	Reasons for delay
17/SC/0014	219973	OPEN WATER - OPEN WATER, Global Post-Market Registry using Waterjet Ablation Therapy for Endoscopic Resection of prostate	07/12/2016	27/07/2017	13/04/2017	17/08/2017	22/08/2017	NA	23/08/2017	31/08/2017	None
17/WM/0106	201079	MOTILITY: Small bowel motility quantified by cine MRI as a predictor of long term response in patients with Crohn's disease commencing biological therapy	05/09/2017	05/09/2017	28/04/2017	29/09/2017	31/10/2017	NA	31/10/2017	25/01/2018	Neither - patients screened but none eligible. 40 day metric not met due to Sponsor delays with contract.
17/SC/0034	217773	ARK - Antibiotic Reduction and Conservation in Hospitals	28/07/2017	09/10/2017	21/03/2017	07/11/2017	14/11/2017	NA	15/11/2017		Neither - protocol design means that patients will not be consented until later on in the study. 40 day metric not met due to delays in correspondance
16/LO/2195	219516	TRITON 2: A Multicenter, Open-label Phase 2 Study of Rucaparib in Patients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency	19/04/2017	18/07/2017	28/03/2017	30/08/2017	04/09/2017	NA	04/09/2017	20/09/2017	40 day metric not achieved due to Sponsor taking 3 weeks to respond to budget negotiations
17/EM/0120	222298	TRITON 3: A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician's Choice of Therapy for Patients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency	19/04/2017	11/07/2017	30/06/2017	30/08/2017	04/09/2017	NA	04/09/2017	04/10/2017	Neither - Protocol design means timings would not adhere to the 70 day metric. 40 day metric not achieved due to Sponsor taking 3 weeks to respond to budget negotiations
17/LO/1802	199038	EQUIPTT - Evaluation of QUIPP app for Triage and Transfer	12/07/2017	14/12/2017	23/11/2017	09/01/2018	11/01/2018	NA	12/02/2018	07/03/2018	Neither - protocol design means that patients will not be consented until later on in the study.

16/EE/0305	190307	PRIMETIME - Post-operative avoidance of radiotherapy in minimal risk women: patient selection using biomarkers	31/03/2016	20/10/2017	03/11/2016	17/01/2018	10/01/2018	NA	31/01/2018	28/02/2018	NHS provider - Delays with setting up cross site and PI availability plus pathology engagement
17/NS/0018	223787	FUTURE: Female Urgency, Trial of Urodynamics as Routine Evaluation (FUTURE study); a superiority randomised clinical trial to evaluate the effectiveness and cost effectiveness of invasive urodynamic investigations in management of women with refractory overactive bladder symptoms	13/12/2017	12/01/2018	11/08/2017	16/02/2018	19/02/2018	NA	05/03/2018	21/03/2018	None
17/NE/0331	229957	ANACONDA: A Prospective, Global, Multicentre, Real World Outcome Study of Fenestrated Endovascular Aneurysm Repair using the Fenestrated Anaconda device	08/08/2017	23/01/2018	20/12/2017	09/02/2018	12/02/2018	NA	21/02/2018	21/03/2018	None
17/SW/0273	235783	Phase III Randomised, Double-masked, Parallel Group, Multicentre Study to Compare the Efficacy, Safety, Pharmacokinetics and Immunogenicity between SB11 (proposed ranibizumab biosimilar) and LucentisÂ® in Subjects with Neovascular Age-related Macular Degeneration	28/11/2017	26/01/2018	22/01/2018	12/03/2018	20/03/2018	NA	08/05/2018	14/05/2018	Sponsor: 40 day metric not achieved due to Sponsor delays in budget negotiations. 70 days not met due to delay in permissions impacting on timeframe.
18/EM/0027	235145	A dose-ranging study of intravitreal OPT-302 in combination with ranibizumab, compared with ranibizumab alone, in participants with neovascular age-related macular degeneration (wet AMD)	16/01/2018	16/01/2018	28/02/2018	29/03/2018	05/04/2018	NA	23/05/2018		Sponsor: 40 day metric not achieved due to Sponsor delays in budget negotiations
18/LO/0133	228164	MIAMI: Can patients with multiple breast cancers in the same breast avoid mastectomy by having multiple lumpectomies to achieve equivalent rates of local breast cancer recurrence? A randomised controlled feasibility study	20/02/2018	24/05/2018	15/03/2018						FP & WP.
17/WA/0383	233958	WHITE 5: A randomised controlled trial comparing contemporary uncemented hemiarthroplasty with standard-of-care cemented hemiarthroplasty for the treatment of displaced intracapsular hip fractures	09/02/2018	09/02/2018	31/01/2018	14/03/2018	15/03/2018	NA	13/04/2018	03/05/2018	70 days not met due to no eligible patients
17/WA/0242	228068	PULSAR: Prostatic Urethral Lift in Subjects with Acute Urinary Retention Study	17/05/2017	21/03/2018	01/08/2017	19/04/2018	19/04/2018	NA	04/05/2018	26/06/2018	70 days not met due to study teams schedule
16/LO/2143	207415	DAIL - Dietetic Assessment and Intervention in Non Small Cell Lung Cancer	11/10/2017	24/05/2018	01/03/2017	26/06/2018	26/06/2018	NA			

18/LO/0782	245936	PAN OPTICA - Randomized, Double Masked, Uncontrolled, Multicenter Phase I/II Study to Evaluate Safety and Tolerability of PAN-90806 Eye Drops, Suspension in Treatment-Naïve Participants with Neovascular Age-Related Macular Degeneration (AMD)	16/04/2018	28/06/2018	22/06/2017						
18/EE/0079	237389	APEX 2 - A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to evaluate the efficacy and safety of two dose levels of BCX7353 as an oral treatment for the prevention of attacks in subjects with Hereditary Angioedema.	16/02/2018	19/06/2018	18/04/2018						
18/SW/0039	229163	BIG BABY - Induction of labour for predicted macrosomia	18/05/2018	18/05/2018	20/03/2018						FP & WP